Journal of Clinical Oncology
Articles in this Issue
Evaluating the effectiveness of immersive virtual reality in reducing distress in patients with cancer receiving chemotherapy: A prospective randomized trial.
11052 Background: Patients diagnosed with cancer commonly face high levels of distress, anxiety, and depressive symptoms along with discomfort or pain, th...
Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).
7544 Background: Belamaf combinations were evaluated for RRMM in the phase 3 DREAMM-7 (belamaf + bortezomib + dexamethasone [BVd]; NCT04246047) and DREAMM...
Impact of neighborhood disadvantage and residential isolation on cognitive outcomes in cancer survivors.
12056 Background: The Social Vulnerability Index (SVI), a composite measure of socioeconomic deprivation, household composition, minority status, and hous...
Transforming lung cancer care for the underserved: Real-world results of SBRT in a safety-net system.
e20082 Background: Stereotactic body radiotherapy (SBRT) is an established treatment for early-stage lung cancer, particularly in patients who are medical...
Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.
1091 Background: Capecitabine at the FDA-approved standard dose (SD) of 1250 mg/m² twice daily for 14 days with a 7-day break, has significant toxicities....
Updated efficacy and safety results from ReBirth, a phase II study of risk-based bladder-sparing therapy for MIBC.
4586 Background: Trimodal therapy (TMT) has achieved long-term survival and persistent oncologic control in selected MIBC patients, however, tailored trea...
<i>MYC</i> amplification as a prognostic biomarker in osteosarcoma: A report from the Children’s Oncology Group.
10045 Background: Osteosarcoma is characterized by complex chromosomal alterations and genomic instability....
Validation of real-world event-free survival (rwEFS) in early-stage triple-negative breast cancer.
11166 Background: Real-world (RW) evidence has been used to demonstrate effectiveness of early-stage cancer treatments. Early-stage clinical endpoints suc...
Advancing racial representation in clinical trials: An analysis of 53 ASCO plenary and late-breaking abstracts using the DRIVE score.
e23007 Background: Despite significant efforts to address inequities in oncology research, underrepresented minoritized populations in clinical research e...
Gender and ethnic disparities in breast cancer and cardiovascular disease-related mortality in United States from 1999-2019: A retrospective analysis.
e13777 Background: Breast cancer and cardiovascular diseases (CVS) are among the leading causes of mortality in the United States, exerting a significant...
Racial and socioeconomic disparities in molecular testing and targeted therapy utilization among patients with advanced non-small cell lung cancer: A National Cancer Database analysis.
e13733 Background: Despite advances in precision medicine for non-small cell lung cancer (NSCLC), disparities in access to molecular testing and targeted...
Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study.
9520 Background: HRDsig can aid in identifying tumors with DNA repair deficiencies, guiding PARP inhibitor (PARPi) use. It expands treatment options beyon...
Pronounced gender-based and regional disparities in lung cancer mortality in the US: Insights from five decades of nationwide mortality data.
8079 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States, necessitating an understanding of long-term morta...
Artificial intelligence-powered spatial analysis of tumor microenvironment in non-small cell lung cancer patients who acquired resistance after EGFR tyrosine kinase inhibitors.
8536 Background: We evaluated dynamic changes in the tumor microenvironment (TME) after EGFR tyrosine kinase inhibitor (TKI) treatment using an artificial...
Trial in progress: Feasibility of CSF and plasma ctDNA in BRAF-altered glioma during treatment with plixorafenib.
TPS2098 Background: Gliomas with BRAF alterations are often difficult to treat in the recurrent setting due to emergent resistance to FDA-approved targete...
Preclinical development of GNTbm-38, a novel class I histone deacetylase inhibitor, while combined with anti-VEGFR TKI or anti-PD-1 Ab: Assessment of immune activation and immune memory in cancer immunotherapy.
2574 Background: Several clinical trials explored ICI-based combinations in MSS mCRC patients, and the promising outcomes are lacking. Histone deacetylase...
AI molecular search engine paired with RNA sequencing analysis to develop potent and selective VEGFR-3 inhibitors.
3104 Background: Tumor angiogenesis (TA) is driven by several VEGF factors and corresponding receptors (VEGFRs). Targeting TA inhibits tumor growth, howev...
Longitudinal changes in credit status for newly diagnosed metastatic colorectal cancer patients (SWOG S1417).
11076 Background: We previously reported that 71% of insured patients with newly diagnosed metastatic colorectal cancer (mCRC) self-reported major financi...
Factors influencing clinical trial enrollment in glioblastoma patients: A retrospective study at the University of Vermont Medical Center.
2054 Background: The standard of care for patients with glioblastoma (GBM) is a combination therapy of radiation and temozolomide. NCCN guidelines recomme...
Exploring demographic and socioeconomic factors in eccrine adenocarcinoma: A National Cancer Database analysis.
e18129 Background: Eccrine adenocarcinoma (EC) is a rare malignancy deriving from the eccrine glands. Current treatment options for EC include wide surgic...
A living systematic literature review (L-SLR) for non–small-cell lung (NSCLC), prostate (PC), and breast cancer (BC), built with an agentic text annotation system powered by large language models (LLM) to assist treatment decision making.
e13657 Background: With demanding schedules, oncologists often struggle to stay updated on the latest clinical trial data from publications, especially wi...
Impact of an early identification model for oncology case management.
e13568 Background: Evidence shows that cancer case management improves patient’s quality-of-life and reduces hospital admissions [1]...
Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.
11504 Background: Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive sarcoma which remains almost universally fatal despite intensive, m...
Communication in AYA survivorship clinical settings: Best practices and challenges.
e22020 Background: Pediatric and adolescent/young adult (AYA) cancer survivors face long-term physical and psychosocial effects of their cancer treatment...
Survival outcomes in locally advanced inoperable NSCLC patients converted to resectable disease by neoadjuvant therapy.
e20075 Background: Locally advanced NSCLC poses a significant therapeutic challenge due to its heterogeneity. NACT, while increasingly employed to convert...